Pulmatrix, Inc. is currently in a transitional wind-down phase, having paused all internal clinical development (including PUR3100, PUR1800, and PUR1900) to conserve cash. Following the termination of its previous merger agreement with Cullgen Inc. in February 2026 due to Chinese regulatory delays, Pulmatrix entered into a definitive reverse merger agreement with Eos SENOLYTIX, Inc. on March 26, 2026. Under the terms of the agreement, the combined company will operate as Eos SENOLYTIX, Inc. (trading under the ticker EOSX or MTXL) and pivot entirely to gerotherapeutic peptide medicines targeting mitochondrial dysfunction in aging-related diseases, such as sarcopenia. Legacy Pulmatrix stockholders are expected to own only approximately 6% of the combined company, resulting in massive dilution. While the merger is backed by $19 million in concurrent private financings (including a closed $1 million Series B Preferred Stock placement), the company's standalone going concern risk is severe. A 'Hold' recommendation is advised as the stock's value is now almost entirely tied to the speculative success of Eos's preclinical platform and the successful closing of the reverse merger in Q3 2026.